Loading
FID-022 is an experimental nanoencapsulated SN38 and irinotecan, topoisomerase I chemotherapy from Fulgent Genetics, in phase 1 trials for advanced solid tumours.
FID-022 is a nanoencapsulated SN38 and irinotecan, topoisomerase I chemotherapy (polyethyloxazoline material) from Fulgent Genetics. SN38 and its prodrug irinotecan encapsulated in a polyethyloxazoline (PEOX) material. Its furthest stage is phase 1, for advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT06694480 recruiting; dose levels 1-4 completed (July 2026 deck). Whether it works in people has not been established unless a trial below reports it.
SN38 and its prodrug irinotecan encapsulated in a polyethyloxazoline (PEOX) material.
1.FID-022 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"FID-022" OR ABSTRACT:"FID-022") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FID-022, not a curated reading list.
Shares Fulgent Genetics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulgent Genetics and the tag pipeline.
Shares Fulgent Genetics and the tag pipeline.
Shares Fulgent Genetics and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/